Risk of obstructive coronary artery disease and major adverse cardiac events in patients with noncoronary atherosclerosis: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program - 16/06/19
, Deepak L. Bhatt, MD, MPH b, Subhash Banerjee, MD c, Thomas J. Glorioso, MS d, Kevin P. Josey, MS d, Rajesh V. Swaminathan, MD a, Thomas M. Maddox, MD e, Ehrin J. Armstrong, MD, MSc d, Claire Duvernoy, MD f, Stephen W. Waldo, MD d, Sunil V. Rao, MD aBackground |
We sought to determine the risk of obstructive coronary artery disease (oCAD) associated with noncoronary atherosclerosis (cerebrovascular disease [CVD] or peripheral arterial disease [PAD]) and major adverse cardiac events following percutaneous coronary intervention (PCI).
Methods |
Rates of the angiographic end point of oCAD were compared among patients with and without noncoronary atherosclerosis undergoing coronary angiography within the Veterans Health Administration between October 2007 and August 2015. The primary angiographic end point of oCAD was defined as left main stenosis ≥50% or any stenosis ≥70% in 1, 2, or 3 vessels. In patients who proceeded to PCI, the rate of the composite clinical end point of death, myocardial infarction, or stroke was compared among those with concomitant noncoronary atherosclerosis (CVD, PAD, or CVD + PAD) versus isolated CAD.
Results |
Among 233,353 patients undergoing angiography, 9.6% had CVD, 12.4% had PAD, and 6.1% had CVD + PAD. Rates of oCAD were 57.9% for neither CVD nor PAD, 66.4% for CVD, 73.6% for PAD, and 80.9% for CVD + PAD. Compared with patients without noncoronary atherosclerosis, the adjusted risk of oCAD with CVD, PAD, or CVD + PAD was 1.03 (95% CI 1.02-1.04), 1.10 (95% CI 1.09-1.11), and 1.12 (95% CI 1.11-1.13), respectively. In patients who underwent PCI, the adjusted hazard for death, myocardial infarction, or stroke among those with CVD, PAD, or CVD + PAD was 1.36 (95% CI 1.26-1.45), 1.53 (95% CI 1.45-1.62), and 1.72 (95% CI 1.59-1.86), respectively.
Conclusions |
In patients undergoing coronary angiography, noncoronary atherosclerosis was associated with increased burden of oCAD and adverse events post-PCI.
Le texte complet de cet article est disponible en PDF.Plan
| Morton J. Kern, MD, served as guest editor for this article. |
Vol 213
P. 47-56 - juillet 2019 Retour au numéro
Article précédent
- Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF
- Sylvia Haas, A John Camm, Jean-Pierre Bassand, Pantep Angchaisuksiri, Frank Cools, Ramon Corbalan, Harry Gibbs, Barry Jacobson, Yukihiro Koretsune, Lorenzo G Mantovani, Frank Misselwitz, Elizaveta Panchenko, Hany Ibrahim Ragy, Janina Stepinska, Alexander GG Turpie, Jitendra PS Sawhney, Jan Steffel, Toon Wei Lim, Karen S Pieper, Saverio Virdone, Freek WA Verheugt, Ajay K Kakkar, for the GARFIELD-AF Investigators 1
- Ticagrelor in patients with heart failure after acute coronary syndromes—Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
- Axel Åkerblom, Daniel M. Wojdyla, Lars Wallentin, Stefan K. James, Flávio de Souza Brito, Philippe Gabriel Steg, Christopher P. Cannon, Hugo A. Katus, Anders Himmelmann, Robert F. Storey, Richard C. Becker, Renato D. Lopes, on behalf of the PLATO Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?